Gennex Laboratories is all set to make Deccan Remedies as its subsidiary company by acquiring additional 6.73% equity Shares i.e., 836,165 from the Existing promoter Shareholders group and in turn the Company will hold 51% equity shares of the Deccan.
As on date, Deccan is a debt free entity and is in the process to implement a manufacturing facility where it will manufacture various API's and other allied products - both with expanded capacity of Gennex as well as developing additional products. Upon Implementation, the Deccan Remedies manufacturing facilities will be as per global regulatory standards of all major markets. This strategic expansion will allow Gennex and Deccan to expand their capabilities and Global reach exponentially - both in terms of products offered and markets catered.
Gennex Laboratories is engaged in the manufacture and export of bulk drugs and intermediates.The product range of the company includes Guaiphenesin, Methocarbamol, Fluconazole and Phenazopyridine.
